BAMS
Bellevue Asset Management (Switzerland) Portfolio holdings
AUM
$656M
This Quarter Return
+10.91%
1 Year Return
+11.48%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$656M
AUM Growth
+$656M
(+7%)
Cap. Flow
-$2.4M
Cap. Flow
% of AUM
-0.37%
Top 10 Holdings %
Top 10 Hldgs %
31%
Holding
140
New
7
Increased
41
Reduced
25
Closed
13
Top Buys
| 1 |
Cardinal Health
CAH
|
$8.17M |
| 2 |
Centene
CNC
|
$5.64M |
| 3 |
Viatris
VTRS
|
$4.88M |
| 4 |
Eagle Bancorp
EGBN
|
$4.88M |
| 5 |
LCI
Lannett Company, Inc.
LCI
|
$4.31M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$13.6M |
| 2 |
Dr. Reddy's Laboratories
RDY
|
$8.31M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
$6.5M |
| 4 |
Abbott
ABT
|
$3.66M |
| 5 |
Tenet Healthcare
THC
|
$3.53M |
Sector Composition
| 1 | Healthcare | 93.1% |
| 2 | Financials | 1.62% |
| 3 | Industrials | 0.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $26M | 3.97% |
217,410
-12,350
| -5% | -$1.48M |
|
2
Biogen
BIIB
$19.4B
| $25.7M | 3.92% |
84,030
+12,260
| +17% | +$3.76M |
|
3
Gilead Sciences
GILD
$140B
| $24.3M | 3.7% |
240,120
-13,930
| -5% | -$1.41M |
|
4
Amgen
AMGN
$155B
| $20M | 3.04% |
123,000
+3,000
| +3% | +$487K |
|
5
Regeneron Pharmaceuticals
REGN
$61.5B
| $19.8M | 3.01% |
36,400
-2,500
| -6% | -$1.36M |
|
6
Medtronic
MDT
$119B
| $19.7M | 3.01% |
256,500
-13,500
| -5% | -$1.04M |
|
7
Illumina
ILMN
$15.8B
| $17.5M | 2.67% |
91,425
+3,800
| +4% | +$729K |
|
|
8
Abbott
ABT
$231B
| $17.1M | 2.61% |
381,500
-81,500
| -18% | -$3.66M |
|
|
9
Viatris
VTRS
$12.3B
| $17M | 2.6% |
315,300
+90,300
| +40% | +$4.88M |
|
10
Becton Dickinson
BDX
$55.3B
| $16.2M | 2.47% |
105,075
+12,770
| +14% | +$1.97M |
|
|
11
Cardinal Health
CAH
$35.5B
| $15.3M | 2.33% |
171,480
+91,480
| +114% | +$8.17M |
|
12
UnitedHealth
UNH
$281B
| $14.1M | 2.15% |
120,000
| – | – |
|
13
Stryker
SYK
$150B
| $13.1M | 1.99% |
140,700
| – | – |
|
14
Teva Pharmaceuticals
TEVA
$21.1B
| $11.6M | 1.77% |
176,720
+7,500
| +4% | +$492K |
|
|
ESRX
15
DELISTED
Express Scripts Holding Company
ESRX
| $10.8M | 1.65% |
124,000
-36,000
| -23% | -$3.15M |
|
|
ENDP
16
DELISTED
Endo International plc
ENDP
| $10.5M | 1.6% |
171,000
+13,000
| +8% | +$796K |
|
|
CYTO
17
DELISTED
Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda)
CYTO
| $10.4M | 1.59% |
2,169,625
| – | – |
|
18
Zimmer Biomet
ZBH
$21B
| $9.8M | 1.49% |
95,500
| – | – |
|
|
ALXN
19
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $9.42M | 1.44% |
49,400
| – | – |
|
20
CVS Health
CVS
$92.8B
| $9.41M | 1.43% |
96,200
+41,200
| +75% | +$4.03M |
|
21
Ligand Pharmaceuticals
LGND
$3.15B
| $8.85M | 1.35% |
81,640
-14,090
| -15% | -$1.53M |
|
22
Incyte
INCY
$16.5B
| $8.57M | 1.31% |
79,000
+2,000
| +3% | +$217K |
|
23
Ionis Pharmaceuticals
IONS
$6.8B
| $8.55M | 1.3% |
138,000
+6,000
| +5% | +$372K |
|
24
Boston Scientific
BSX
$156B
| $8.48M | 1.29% |
460,000
+60,000
| +15% | +$1.11M |
|
25
McKesson
MCK
$85.4B
| $8.48M | 1.29% |
43,000
+2,000
| +5% | +$394K |
|